Daiichi Sankyo Secures FDA Priority Review for ADC Therapy
Tokyo, Japan & Basking Ridge, New Jersey | April 13, 2026 Daiichi Sankyo, in collaboration with Merck & Co.,...
Merck
Advertisement
Merck Partners Infinimmune in $838M Antibody Discovery Deal
RAHWAY, N.J., USA — March 31, 2026 Merck & Co. has entered into a strategic antibody discovery collaboration with...
Merck to Acquire Terns to Strengthen CML Pipeline
RAHWAY, New Jersey & FOSTER CITY, California, March 25, 2026 Merck & Co. has announced a definitive agreement to...
Quotient Therapeutics, Merck Sign $2.2B IBD Deal
CAMBRIDGE, MASSACHUSETTS, March 24, 2026 Quotient Therapeutics has announced a multi-year research collaboration with Merck & Co. to discover...
Flare and Merck Partner to Advance FX-909 Combo in Cancer
CAMBRIDGE, MA – October 21, 2025 – Flare Therapeutics Inc. (FlareTx), a clinical-stage biotechnology company pioneering therapies that target...
Advertisements
Merck’s Two-Drug HIV Therapy Shows Strong Phase 3 Efficacy
RAHWAY, N.J. – October 15, 2025 — Merck (NYSE: MRK) announced new Phase 3 trial results for its investigational,...
MilliporeSigma Expands Protein A Capabilities with JSR Life Sciences Acquisition
Burlington, Massachusetts – October 15, 2025 – MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt,...
Eisai Highlights Groundbreaking Oncology Data at ESMO 2025 Congress
NUTLEY, N.J., Oct. 2, 2025 — Eisai Inc. announced today the presentation of its expansive oncology portfolio at the...
Merck Reports Positive HYPERION Results for Pulmonary Hypertension Therapy
RAHWAY, N.J., Sept. 30, 2025 – Merck (NYSE: MRK), known as MSD outside the United States and Canada, today...
FDA Clears Merck’s Keytruda QLEX for Subcutaneous Solid Tumor Use
RAHWAY, N.J. – September 20, 2025 — Merck (NYSE: MRK) announced that the U.S. Food and Drug Administration (FDA)...
Advertisement
